This suggests that pharmacological inhibition of G6PD is still effective in the prostate cancer–bone microenvironment and can overcome the increase in G6PD expression induced by the bone microenvironment, providing further support for targeting the PPP in prostate cancer bone metastasis. Here, G6PD is linked to prostate carcinoma.